7OC0 Stock Overview
A precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
OncoCyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.18 |
| 52 Week High | US$15.50 |
| 52 Week Low | US$2.76 |
| Beta | 1.53 |
| 11 Month Change | 0% |
| 3 Month Change | -94.29% |
| 1 Year Change | -98.84% |
| 33 Year Change | -99.35% |
| 5 Year Change | -99.37% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7OC0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | -1.8% |
| 1Y | -98.8% | -14.9% | 13.2% |
Return vs Industry: 7OC0 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 7OC0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 7OC0 volatility | |
|---|---|
| 7OC0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7OC0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 7OC0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 76 | Josh Riggs | www.oncocyte.com |
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.
OncoCyte Corporation Fundamentals Summary
| 7OC0 fundamental statistics | |
|---|---|
| Market cap | €21.48m |
| Earnings (TTM) | -€16.24m |
| Revenue (TTM) | €1.04m |
20.7x
P/S Ratio-1.3x
P/E RatioIs 7OC0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7OC0 income statement (TTM) | |
|---|---|
| Revenue | US$1.10m |
| Cost of Revenue | US$1.03m |
| Gross Profit | US$75.00k |
| Other Expenses | US$17.27m |
| Earnings | -US$17.20m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.09 |
| Gross Margin | 6.81% |
| Net Profit Margin | -1,562.03% |
| Debt/Equity Ratio | 0% |
How did 7OC0 perform over the long term?
See historical performance and comparison